摘要
目的:探讨CA125、CA199、CEA联合检测在妇科肿瘤临床诊断中的应用价值。方法:选择妇科恶性肿瘤组65例、妇科良性肿瘤组55例、健康对照组70例,采用自动荧光磁微粒酶免分析法检测血清中CA199、CA125的含量,采用光激化学发光法检测血清中CEA的含量。结果:妇科恶性肿瘤组血清中CA125、CA199、CEA的水平明显高于妇科良性肿瘤组及对照组,差异有统计学意义(P<0.01);妇科良性肿瘤组血清中CA125、CA199、CEA的水平高于对照组,差异有统计学意义(P<0.01);CA125、CA199、CEA联合检测对早期妇科肿瘤诊断的阳性率较单独检测高,差异有统计学意义(P<0.05);良性组、恶性组联合检测ROC曲线下面积大于单项检测曲线下面积。结论:联合检测可提高对妇科肿瘤早期诊断的阳性率,对妇科良恶性的诊断及鉴别诊断有重要价值。
Objective: To study value of combined detection of CA125, CA199 and CEA for diagnosis of gynae- eology cancer. Methods: The serum levels of CA125, CA199 and CEA of 65 patients with gynaecology carcino- ma, 55 patients with benign gynaecology tumor and 70 healthy women were detected in immunechemiluminescence assay. Results: The serum levels of CA125, CA199 and CEA in gynaeeology cancer group were significantly high- er than those in the benign gynaecology tumor group and healthy women group(P〈0.01). The serum levels of CA125, CA199 and CEA in benign gynaecology tumor group were higher than those in the healthy women group (P〈0.01). In early stage of gynaecology carcinoma, the positive rate of CA125, CA199 and CEA combined detec- tion was higher than that of CA125 detection alone(P〈0.05). The benign and malignant group joint test area un- der of ROC curves was greater than the single detection. Conclusion: The combined detection may improve the positive rate of diagnosis of early gynaecology tumour, has the important values in accessory diagnosis and differen- tial diagnosis of gynaecology tumors.
出处
《生物技术通讯》
CAS
2012年第6期854-856,共3页
Letters in Biotechnology
关键词
妇科肿瘤
肿瘤标志物
联合检测
tumor marker
combined detection
gynaecology tumour